BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy
Aims In treating patients with melanoma, the order in which therapy is administered, choosing between targeted therapy and immune checkpoint inhibition, has garnered growing interest.Patients and Methods We conducted a retrospective, real-world analysis of patients with advanced melanoma undergoing...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Melanoma Management |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20450885.2024.2432826 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850220126761123840 |
|---|---|
| author | Ilaria Proietti Elena De Falco Luca Pacini Alessandra Spagnoli Velia Melone Vincenzo Petrozza Claudio Di Cristofano Giorgio Mangino Giovanna Romeo Paolo Rosa Antonella Calogero Concetta Potenza |
| author_facet | Ilaria Proietti Elena De Falco Luca Pacini Alessandra Spagnoli Velia Melone Vincenzo Petrozza Claudio Di Cristofano Giorgio Mangino Giovanna Romeo Paolo Rosa Antonella Calogero Concetta Potenza |
| author_sort | Ilaria Proietti |
| collection | DOAJ |
| description | Aims In treating patients with melanoma, the order in which therapy is administered, choosing between targeted therapy and immune checkpoint inhibition, has garnered growing interest.Patients and Methods We conducted a retrospective, real-world analysis of patients with advanced melanoma undergoing immunotherapy or targeted therapy as first-line at a single center.Results A total of 88 patients diagnosed with melanoma were identified. At 7 years, in this cohort, 68.4% (95% CI: 55.9%-83.6%) of patients were alive. In all, 47 tumors harbored BRAF mutations; 10 patients who did not receive therapy were excluded from this subgroup. Of the 37 patients with a BRAF mutation, 29 received first-line targeted therapy and 8 received first-line immunotherapy. At 2 years, 28 (76%) patients were alive and 9 (24%) had died. Of the 28 survivors, 22 received first-line targeted therapy and 6 received first-line immunotherapy. In addition, 29 patients were administered a MEK inhibitor in first line. Of these, 66.4% (95% CI: 48.3–91.2) of patients were alive at 7 years.Conclusions There was no significant difference between survival and first-line immunotherapy or first-line targeted therapy. Additional studies are required to establish whether front-line immunotherapy is linked to more effective long-term disease control compared to first-line targeted therapy. |
| format | Article |
| id | doaj-art-e3b4f50ea2d244aeab077e4345bb6c49 |
| institution | OA Journals |
| issn | 2045-0885 2045-0893 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Melanoma Management |
| spelling | doaj-art-e3b4f50ea2d244aeab077e4345bb6c492025-08-20T02:07:10ZengTaylor & Francis GroupMelanoma Management2045-08852045-08932024-12-0111110.1080/20450885.2024.2432826BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapyIlaria Proietti0Elena De Falco1Luca Pacini2Alessandra Spagnoli3Velia Melone4Vincenzo Petrozza5Claudio Di Cristofano6Giorgio Mangino7Giovanna Romeo8Paolo Rosa9Antonella Calogero10Concetta Potenza11Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit “Daniele Innocenzi”, Sapienza University of Rome, Latina, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, ItalyDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit “Daniele Innocenzi”, Sapienza University of Rome, Latina, ItalyAims In treating patients with melanoma, the order in which therapy is administered, choosing between targeted therapy and immune checkpoint inhibition, has garnered growing interest.Patients and Methods We conducted a retrospective, real-world analysis of patients with advanced melanoma undergoing immunotherapy or targeted therapy as first-line at a single center.Results A total of 88 patients diagnosed with melanoma were identified. At 7 years, in this cohort, 68.4% (95% CI: 55.9%-83.6%) of patients were alive. In all, 47 tumors harbored BRAF mutations; 10 patients who did not receive therapy were excluded from this subgroup. Of the 37 patients with a BRAF mutation, 29 received first-line targeted therapy and 8 received first-line immunotherapy. At 2 years, 28 (76%) patients were alive and 9 (24%) had died. Of the 28 survivors, 22 received first-line targeted therapy and 6 received first-line immunotherapy. In addition, 29 patients were administered a MEK inhibitor in first line. Of these, 66.4% (95% CI: 48.3–91.2) of patients were alive at 7 years.Conclusions There was no significant difference between survival and first-line immunotherapy or first-line targeted therapy. Additional studies are required to establish whether front-line immunotherapy is linked to more effective long-term disease control compared to first-line targeted therapy.https://www.tandfonline.com/doi/10.1080/20450885.2024.2432826Melanomafirst lineimmunotherapytargeted therapyreal-worldBRAF |
| spellingShingle | Ilaria Proietti Elena De Falco Luca Pacini Alessandra Spagnoli Velia Melone Vincenzo Petrozza Claudio Di Cristofano Giorgio Mangino Giovanna Romeo Paolo Rosa Antonella Calogero Concetta Potenza BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy Melanoma Management Melanoma first line immunotherapy targeted therapy real-world BRAF |
| title | BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy |
| title_full | BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy |
| title_fullStr | BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy |
| title_full_unstemmed | BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy |
| title_short | BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy |
| title_sort | braf mutant melanoma management a single center retrospective analysis of patients treated with sequential therapy |
| topic | Melanoma first line immunotherapy targeted therapy real-world BRAF |
| url | https://www.tandfonline.com/doi/10.1080/20450885.2024.2432826 |
| work_keys_str_mv | AT ilariaproietti brafmutantmelanomamanagementasinglecenterretrospectiveanalysisofpatientstreatedwithsequentialtherapy AT elenadefalco brafmutantmelanomamanagementasinglecenterretrospectiveanalysisofpatientstreatedwithsequentialtherapy AT lucapacini brafmutantmelanomamanagementasinglecenterretrospectiveanalysisofpatientstreatedwithsequentialtherapy AT alessandraspagnoli brafmutantmelanomamanagementasinglecenterretrospectiveanalysisofpatientstreatedwithsequentialtherapy AT veliamelone brafmutantmelanomamanagementasinglecenterretrospectiveanalysisofpatientstreatedwithsequentialtherapy AT vincenzopetrozza brafmutantmelanomamanagementasinglecenterretrospectiveanalysisofpatientstreatedwithsequentialtherapy AT claudiodicristofano brafmutantmelanomamanagementasinglecenterretrospectiveanalysisofpatientstreatedwithsequentialtherapy AT giorgiomangino brafmutantmelanomamanagementasinglecenterretrospectiveanalysisofpatientstreatedwithsequentialtherapy AT giovannaromeo brafmutantmelanomamanagementasinglecenterretrospectiveanalysisofpatientstreatedwithsequentialtherapy AT paolorosa brafmutantmelanomamanagementasinglecenterretrospectiveanalysisofpatientstreatedwithsequentialtherapy AT antonellacalogero brafmutantmelanomamanagementasinglecenterretrospectiveanalysisofpatientstreatedwithsequentialtherapy AT concettapotenza brafmutantmelanomamanagementasinglecenterretrospectiveanalysisofpatientstreatedwithsequentialtherapy |